Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Skye Bioscience ( (SKYE) ) has provided an announcement.
On June 6, 2025, Skye Bioscience held its 2025 Annual Meeting of Stockholders, where 82.2% of the shares entitled to vote were represented. Key outcomes included the election of six directors for a one-year term, the ratification of Marcum as the independent accounting firm, and the approval of executive compensation. Additionally, the company decided to conduct annual advisory votes on executive compensation, aligning with stockholder preferences.
The most recent analyst rating on (SKYE) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Skye Bioscience stock, see the SKYE Stock Forecast page.
Spark’s Take on SKYE Stock
According to Spark, TipRanks’ AI Analyst, SKYE is a Underperform.
Skye Bioscience’s overall stock score is primarily hindered by significant financial challenges, including zero revenue and continuous losses. Despite strong earnings call highlights and a substantial cash position, the bearish technical analysis and valuation difficulties weigh heavily on the score.
To see Spark’s full report on SKYE stock, click here.
More about Skye Bioscience
Average Trading Volume: 708,754
Technical Sentiment Signal: Hold
Current Market Cap: $73.43M
For a thorough assessment of SKYE stock, go to TipRanks’ Stock Analysis page.